drugset
drugset / Trial / NCT00451048

Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

NCT00451048 ↗

Phase 2 Completed 10 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well sunitinib works in treating patients with myelodysplastic syndromes or chronic myelomonocytic leukemia. Sunitinib may stop the growth of abnormal cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2007-02
Primary completion
2011-09
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Sunitinib Small molecule — Oral

Indications

chronic myelomonocytic leukemia myelodysplastic syndrome